Optical coherence tomography and visual field testing both essential

Article

Both structural and functional testing are important when diagnosing glaucoma and managing the condition in patients who have the disease.

"The question of imaging versus visual fields in glaucoma is a tongue-in-cheek discussion to some degree," Dr. Wooldridge said. "You really need both."

Visual field testing (VFT) using standard automated perimetry faces several "charges" in some quarters, in that VFT:

Advances in perimetry, such as short wavelength automated perimetry (SWAP) and frequency doubling technology, have increased sensitivity compared with standard automated perimetry. These newer technologies allow optometrists to detect VFL earlier in the disease process. They also utilize stimuli and patterns of presentation that target and allow the monitoring of select subpopulations of retinal ganglion cells.

In addition, improvements in software allow test times to be halved, reducing patient fatigue and increasing the reliability of the results, Dr. Wooldridge said. In addition, achromatic VFTs are the primary measure of progression in more advanced disease.

No single "best" perimeter or VFT for the early detection of glaucomatous damage exists, Dr. Wooldridge said. Some patients' damage will be detected first by SWAP, some by FDT, and some by standard automated perimetry.

The importance of using imaging along with visual fields can't be overestimated because structural damage precedes functional change; nerve fiber layer injury can be observed up to 6 years before visual field defects become evident, as noted by Sommer, Katz, Quigley, et al.

Imaging via the current state-of-the-art spectral domain optical coherence tomography (OCT) provides information about the optic nerve head, ganglion cell complex, retinal nerve fiber layer (RNFL), and other structures, and it enables glaucoma progression analyses that include thickness maps, changes in optic disc parameters, temporal superior nasal inferior temporal graph comparisons, RNFL trend analysis, and changes in RNFL parameters.

Recent Videos
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.